UK markets closed

Revance Therapeutics, Inc. (RVNC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.0200-0.1400 (-4.43%)
At close: 04:00PM EDT
3.0300 +0.01 (+0.33%)
After hours: 07:58PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
240,202
234,040
132,565
77,798
15,325
Cost of revenue
76,787
74,363
51,667
23,410
4,769
Gross profit
163,415
159,677
80,898
54,388
10,556
Operating expenses
Research development
76,271
79,410
101,286
116,255
125,795
Selling general and administrative
299,232
292,238
219,696
198,821
151,846
Total operating expenses
385,867
382,012
353,067
329,064
283,718
Operating income or loss
-222,452
-222,335
-272,169
-274,676
-273,162
Interest expense
20,115
19,356
16,474
6,273
15,148
Total other income/expenses net
-95,484
-95,280
-71,970
-698
-721
Income before tax
-324,740
-323,686
-355,722
-281,310
-284,709
Income tax expense
-
300
700
0
-2,620
Income from continuing operations
-325,040
-323,986
-356,422
-281,310
-282,089
Net income
-317,345
-323,986
-356,422
-281,310
-282,089
Net income available to common shareholders
-317,345
-323,986
-356,422
-281,310
-282,089
Basic EPS
-5.10
-3.83
-4.90
-4.17
-4.86
Diluted EPS
-5.10
-3.83
-4.90
-4.17
-4.86
Basic average shares
82,914
84,599
72,713
67,508
58,009
Diluted average shares
82,914
84,599
72,713
67,508
58,009